...
首页> 外文期刊>Clinical and experimental pharmacology & physiology >PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.
【24h】

PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.

机译:PI3K / Akt / mTOR途径双重抑制剂BEZ235抑制结肠癌干细胞的干性。

获取原文
获取原文并翻译 | 示例

摘要

Colon cancer is one of the most common cancers worldwide with high mortality. A major issue in colon cancer treatment is drug-resistance and metastasis that have been ascribed to the cancer stem cells. In this study, colon cancer stem cells were isolated through sphere culture and verified with the cancer stem cell markers CD133, CD44, and CD24. It was demonstrated that the PI3K/Akt/mTOR signalling pathway was highly activated in the colon cancer stem cells and that inhibition of the PI3K/Akt/mTOR pathway by the inhibitor BEZ235 suppressed the colon cancer stem cell proliferation with reduced stemness indicated by CD133 and Lgr5 expressions. Treatment with insulin as a known activator of the PI3K/Akt pathway increased CD133 expression and decreased the effects of BEZ235 on colon cancer proliferation and survival. The data presented here collectively suggest that the PI3K/Akt/mTOR pathway underpins the stemness of colon cancer stem cells and BEZ235 is potentially a good drug candidate for treatment of colon cancer drug resistance and metastasis.
机译:结肠癌是全球死亡率最高的最常见癌症之一。结肠癌治疗中的一个主要问题是归因于癌症干细胞的耐药性和转移。在这项研究中,结肠癌干细胞通过球形培养分离,并用癌症干细胞标记CD133,CD44和CD24进行验证。结果表明,PI3K / Akt / mTOR信号通路在结肠癌干细胞中被高度激活,并且抑制剂BEZ235对PI3K / Akt / mTOR信号通路的抑制作用抑制了结肠癌干细胞的增殖,其干度降低,如CD133和Lgr5表达式。用胰岛素作为PI3K / Akt途径的已知激活剂进行治疗可增加CD133表达,并降低BEZ235对结肠癌增殖和存活的影响。此处提供的数据共同表明,PI3K / Akt / mTOR途径是结肠癌干细胞干性的基础,而BEZ235可能是治疗结肠癌耐药性和转移的良好候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号